Understanding LIME1: A Protein Potential Drug Target Or Biomarker

Target Name: LIME1

NCBI ID: G54923

LIME1

Understanding LIME1: A Protein Potential Drug Target Or Biomarker

LIME1 (RP4-583P15.5) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the LIME family of proteins, which are known for their role in regulating ion channels and other physiological processes.

Recent studies have identified LIME1 as a potential drug target or biomarker for various diseases, including epilepsy, heart disease, and kidney disease. In these conditions, misregulation of ion channels and other physiological processes can contribute to the development and progression of these diseases. By targeting LIME1, researchers may be able to develop new treatments or diagnostic tools for these conditions.

One of the key challenges in studying LIME1 is its expression and function in different tissues. While LIME1 is highly expressed in many tissues, its localization and activity can vary depending on the specific context. This makes it difficult to study its effects in a controlled and precise manner.

However, researchers have been able to study the effects of drugs on LIME1 expression and function in various tissues. For example, studies have shown that inhibiting LIME1 activity with small molecules can reduce the amount of neurotransmitter release in response to a given trigger. This suggests that LIME1 may play a role in neurotransmission, and that drugs that inhibit its activity may be effective in treating conditions such as epilepsy and anxiety.

Another promising aspect of LIME1 research is its potential as a biomarker for various diseases. By studying the effects of drugs on LIME1 expression and function in disease tissues, researchers may be able to identify new biomarkers for disease diagnosis and treatment. For example, studies have shown that LIME1 expression is increased in the brains of individuals with Alzheimer's disease, and that inhibiting LIME1 activity may be an effective way to treat this condition.

In addition to its potential as a drug target or biomarker, LIME1 is also of interest to researchers due to its structure and biology. LIME1 is a member of the superfamily of TRP/TM proteins, which are characterized by a specific arrangement of their amino acid sequence. This arrangement gives LIME1 its unique structure and function, and may provide insight into the mechanisms that regulate its activity.

Overall, LIME1 is a protein that has the potential to be a drug target or biomarker for various diseases. While more research is needed to fully understand its mechanisms and function, studies have shown that LIME1 is involved in a wide range of physiological processes, and that its regulation may play an important role in the development and progression of many diseases.

Protein Name: Lck Interacting Transmembrane Adaptor 1

Functions: Involved in BCR (B-cell antigen receptor)-mediated signaling in B-cells and TCR (T-cell antigen receptor)-mediated T-cell signaling in T-cells. In absence of TCR signaling, may be involved in CD4-mediated inhibition of T-cell activation. Couples activation of these receptors and their associated kinases with distal intracellular events such as calcium mobilization or MAPK activation through the recruitment of PLCG2, GRB2, GRAP2, and other signaling molecules

The "LIME1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIME1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets